TLDR
- Novartis stock slipped 0.42% to $122.91 despite reporting strong Q3 2025 results.
- Net sales rose 8% to $13.9 billion, while operating income jumped 24% to $4.5 billion.
- Net income surged 23% to $3.9 billion, with EPS climbing 29%.
- Generics weighed on Entresto sales, offset by growth from Kisqali, Kesimpta, and Pluvicto.
- Novartis confirmed 2025 guidance and continues $30 billion in acquisitions, including Avidity.
Novartis AG (NYSE: NVS) traded at $122.91 as of October 29, 2025, down 0.42% after reporting strong third-quarter earnings.
Novartis AG, NVS
Despite robust results, the stock slipped as generics began biting into sales of its top-selling heart drug, Entresto.
Strong Financial Performance in Q3 2025
Novartis delivered solid earnings growth during the third quarter of 2025, supported by rising demand for its newer treatments and strategic R&D investments. The company reported net sales of USD 13.9 billion, an 8% year-over-year increase, with major contributions from Kisqali, Kesimpta, and Pluvicto.
Novartis, $NVS, Q3-25 Results:
📊 Adj. EPS: $2.25 🔴
💰 Revenue: $13.91B 🟢
📈 Net Income: $3.93B
🔎 FDA approved Rhapsido for CSU and pipeline assets like ianalumab, Scemblix, and Pluvicto posted strong Phase III data. pic.twitter.com/5RJOaqM7cU— EarningsTime (@Earnings_Time) October 28, 2025
Operating income rose 24% to USD 4.5 billion, reflecting higher product sales and lower impairments. Net income climbed 23% to USD 3.9 billion, while earnings per share improved by 29%. The results underscore Novartis’s resilience and effective cost management amid competitive market pressures.
Impact of Generic Competition
Despite overall growth, Novartis faced headwinds from the entry of generic competitors impacting Entresto, its key heart-failure therapy. The company’s adjusted operating income, excluding special items, rose 6% to $5.46 billion, slightly above consensus expectations of $5.4 billion.
The pharmaceutical giant continues to expand through acquisitions to offset declining revenues from aging drugs. It has completed up to $30 billion in acquisitions and licensing deals in 2025, including a $12 billion acquisition of U.S. biotech firm Avidity, strengthening its drug pipeline and future growth prospects.
Focus on Innovation and Market Expansion
Novartis remains focused on advancing high-value medicines and strengthening its global presence. The company continues to invest in AI-driven research and next-generation technology platforms, with key growth markets in the U.S., China, Germany, and Japan.
Having raised its forecasts twice in 2025, Novartis reaffirmed its guidance, expecting full-year sales to grow by a “high single-digit” percentage and adjusted operating income by a “low-teens” percentage.
Performance Overview
Despite the stock’s minor decline following the report, Novartis has delivered strong returns over time. As of October 29, 2025, NVS had a year-to-date return of 30.91% and a one-year return of 10.19%. Over three and five years, total returns stood at 70.85% and 90.82%, respectively, nearly matching the MSCI World benchmark.
Novartis’s third-quarter performance highlights its strong fundamentals, innovative pipeline, and disciplined execution, positioning the company for sustained growth even amid increasing generic competition.
Considering a new stock? You may want to see what’s on our watchlist first.
Our team at Knockout Stocks follows top-performing analysts and market-moving trends to spot potential winners early. We’ve identified five stocks gaining quiet attention that could be worth watching now. Create your free account to unlock the full report and get ongoing stock insights.Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
